• 1. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 2. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 3. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Recent Advances in Carrageenan (9000-07-1) Research: Applications and Innovations in Chemical Biomedicine

Carrageenan (EINECS 232-524-2, CAS 9000-07-1), a family of linear sulfated polysaccharides extracted from red seaweed, has garnered significant attention in the chemical biomedicine field due to its versatile applications in drug delivery, wound healing, and antimicrobial formulations. Recent studies have further elucidated its molecular mechanisms and expanded its potential uses in therapeutic and diagnostic contexts. This research briefing synthesizes the latest findings on carrageenan, focusing on its structural properties, functional modifications, and emerging biomedical applications.

A 2023 study published in Carbohydrate Polymers demonstrated that kappa-carrageenan (a subtype of 9000-07-1) exhibits enhanced mucoadhesive properties when cross-linked with chitosan, enabling targeted drug delivery to mucosal tissues. The research team utilized atomic force microscopy (AFM) and rheological analysis to characterize the hybrid hydrogel's mechanical strength, revealing a 40% improvement in sustained release kinetics compared to conventional formulations. These findings underscore carrageenan's potential in treating inflammatory bowel diseases (IBD) and oral mucositis.

Innovative work from the University of Tokyo (2024) has explored carrageenan's role in antiviral therapeutics. Lambda-carrageenan (9000-07-1) showed potent inhibition of SARS-CoV-2 pseudovirus entry in vitro by competitively binding to the spike protein's receptor-binding domain (RBD). Molecular dynamics simulations confirmed that the sulfation pattern of carrageenan creates electrostatic interactions with viral glycoproteins, suggesting its utility as a broad-spectrum viral entry inhibitor. Clinical trials are underway to evaluate nasal sprays containing 0.12% iota-carrageenan for COVID-19 prophylaxis.

In tissue engineering, carrageenan's thermo-reversible gelation properties have been leveraged to create 3D bioprinted scaffolds. A breakthrough study in Advanced Functional Materials (2024) reported a carrageenan-gelatin methacryloyl (GelMA) composite that maintains structural integrity at physiological temperatures while supporting chondrocyte proliferation. The scaffold's sulfated groups were found to mimic native glycosaminoglycans, enhancing extracellular matrix production by 2.3-fold compared to alginate controls.

Despite these advances, challenges remain in standardizing carrageenan's pharmaceutical-grade production. Recent analytical techniques such as size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) have improved batch-to-batch consistency monitoring. The European Pharmacopoeia 11.0 (2023) has established new purity criteria for 9000-07-1, specifically limiting heavy metal content to <10 ppm and residual solvents to <0.5%.

Looking forward, the integration of carrageenan with nanotechnology presents exciting opportunities. Preliminary data from MIT (2024) shows that carrageenan-coated gold nanoparticles exhibit pH-dependent drug release in tumor microenvironments, achieving 78% tumor regression in murine models of triple-negative breast cancer. This builds upon earlier work demonstrating carrageenan's ability to stabilize therapeutic proteins against aggregation during lyophilization.

In conclusion, the evolving research landscape positions carrageenan (9000-07-1) as a multifaceted biomaterial with expanding roles in precision medicine. Future directions include optimizing its degree of sulfation for specific applications and addressing regulatory considerations for clinical translation. The compound's natural origin, biocompatibility, and tunable properties continue to drive innovation across therapeutic modalities.

• 9000-69-5(Pectin)
• 9002-18-0(Agar)
• 25990-10-7(Polygalacturonic acid)
• 9000-30-0(Guar gum)
• 9005-32-7(Alginic Acid)
• 96-82-2(Lactobionic acid)
• 9000-70-8(Gelatins)
• 11138-66-2(Xanthan Gum)
• 7758-29-4(Sodium Triphosphate)
• 9005-38-3(Sodium alginate)